

Exelixis (NASDAQ:EXEL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided...
You can purchase shares of Exelixis (NASDAQ:EXEL) through any online brokerage.
Other companies in Exelixis’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Exelixis has a consensus price target of $51.74.
The stock price for Exelixis (NASDAQ: EXEL) is $68.65 last updated November 5, 2026 at 6:04 PM EST.
There are no upcoming dividends for Exelixis.
Exelixis does not have any upcoming earnings scheduled.
There is no upcoming split for Exelixis.
Exelixis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and...